In light of current treatment modalities, the nurse should anticipate that the client newly diagnosed with schizophrenia will most likely be prescribed what drug?

Lisdexamfetamine is a prodrug of dextroamphetamine, which means that it is converted into dextroamphetamine in the body. It is a central nervous system (CNS) stimulant medication used to treat attention deficit hyperactivity disorder (ADHD). Lisdexamfetamine has a lower risk of abuse and dependence compared to other amphetamines, such as methamphetamine, dextroamphetamine, and dextroamphetamine and amphetamine combination products.

Lisdexamfetamine is a long-acting medication that is taken once daily, and it has a slower onset of action compared to other amphetamines. This slower onset of action may make it less attractive for abuse or misuse, as individuals seeking immediate effects may be less likely to use lisdexamfetamine.

However, it is important to note that all amphetamines have the potential for abuse and dependence, and they should only be used under the close supervision of a healthcare provider. Individuals taking amphetamines for ADHD should be closely monitored for signs of misuse, and the medication should be discontinued if misuse or abuse is suspected.

Calcitonin is a medication used to treat postmenopausal osteoporosis in older adults. It works by inhibiting bone resorption and decreasing the breakdown of bone tissue. Calcitonin is available in several forms, including intranasal spray, subcutaneous injection, and intravenous infusion. However, for the treatment of postmenopausal osteoporosis, calcitonin is most commonly administered via intranasal spray.

Intranasal calcitonin is easy to use and well-tolerated by most clients. It is absorbed through the nasal mucosa and reaches peak blood levels within 30-60 minutes after administration. The medication is usually administered once daily, alternating nostrils with each dose.

Other routes of administration, such as subcutaneous injection and intravenous infusion, may be used in certain situations, such as for the treatment of Paget's disease of bone or hypercalcemia. However, these routes of administration are less commonly used for the treatment of postmenopausal osteoporosis in older adults. The healthcare provider will determine the appropriate route of administration based on the individual client's needs and medical history.